LOGO
LOGO

COVID-19: Drugs in Development

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
GC Biopharma Corp.
(006280.KS)
GC4006A -Covid-19 Vaccine candidate
South Korea’s Ministry of Food and Drug Safety approved IND application to begin Phase 1 study of GC4006A- reported on Dec. 22, 2025.
An IND application has been submitted to the Ministry of Food and Drug Safety (MFDS) in South Korea for a Phase 1 clinical trial of GC4006A- reported on Sept. 22, 2025.
Phase 2 IND submission in the second half of 2026
-
12/23/2025
CastleVax
CVAX-01- Covid-19 Vaccine Candidate
Initiated Phase 2 study of intranasal, COVID-19 vaccine candidate CVAX-01- reported on Nov 4, 2025.
-
-
11/28/2025
Biotechnology Weekly Update - March 19, 2025

March 19, 2025 09:33 ET
This week's video covers several intriguing topics: a merger of two pharma companies with a troubled past to create a global, diversified pharmaceuticals leader; a novel therapy in the works that could change the treatment landscape of Hunter syndrome, if approved; and a partnership to unlock Petrelintide’s potential for obesity treatment. Additionally, we explore the CDC's investigation into a potential link between vaccines and autism, amid the growing number of autism diagnoses.

Latest Updates on COVID-19